183 related articles for article (PubMed ID: 35795681)
1. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.
Del Rio ML; Perez-Simon JA; Rodriguez-Barbosa JI
Front Immunol; 2022; 13():887348. PubMed ID: 35795681
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1
Del Rio ML; de Juan CY; Roncador G; Caleiras E; Álvarez-Esteban R; Pérez-Simón JA; Rodriguez-Barbosa JI
Front Immunol; 2023; 14():1113858. PubMed ID: 37033927
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
4. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
[TBL] [Abstract][Full Text] [Related]
5. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
Bai R; Cui J
Front Immunol; 2022; 13():886931. PubMed ID: 35634343
[TBL] [Abstract][Full Text] [Related]
6. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
[TBL] [Abstract][Full Text] [Related]
7. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Sivori S; Vacca P; Del Zotto G; Munari E; Mingari MC; Moretta L
Cell Mol Immunol; 2019 May; 16(5):430-441. PubMed ID: 30778167
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow-derived mesenchymal stem cells inhibit CD8
Liu Z; Mi F; Han M; Tian M; Deng L; Meng N; Luo J; Fu R
Clin Exp Immunol; 2021 Jul; 205(1):53-62. PubMed ID: 33735518
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
12. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Benson DM; Bakan CE; Mishra A; Hofmeister CC; Efebera Y; Becknell B; Baiocchi RA; Zhang J; Yu J; Smith MK; Greenfield CN; Porcu P; Devine SM; Rotem-Yehudar R; Lozanski G; Byrd JC; Caligiuri MA
Blood; 2010 Sep; 116(13):2286-94. PubMed ID: 20460501
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
15. "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
Mensali N; Dillard P; Fayzullin A; Köksal H; Gaudernack G; Kvalheim G; Inderberg EM; Wälchli S
FASEB J; 2021 Sep; 35(9):e21750. PubMed ID: 34424568
[TBL] [Abstract][Full Text] [Related]
16. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Yang L; Shen M; Xu LJ; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO
Sci Rep; 2017 Aug; 7(1):7958. PubMed ID: 28801607
[TBL] [Abstract][Full Text] [Related]
17. NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.
Dunai C; Murphy WJ
J Clin Invest; 2018 Oct; 128(10):4251-4253. PubMed ID: 30198909
[TBL] [Abstract][Full Text] [Related]
18. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
19. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
20. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
